We investigate the drivers of TB, including HIV co-infection, drug resistance and the social determinants that shape who is most affected and who gets access to care.

Our researchers improve screening and diagnosis, lead major international trials, and generate the evidence needed to strengthen treatment, particularly for drug-resistant TB and underserved populations.

On antimicrobial resistance, we take a multidisciplinary approach to understanding how resistance emerges and spreads across human, animal and environmental settings. Our work spans molecular microbiology, clinical research, health economics and social science, helping develop solutions that are both scientifically robust and practical in low-resource settings.

Working with partners across high-burden countries, LSTM turns research into real-world impact, from better diagnostics and shorter treatment regimens to stronger stewardship, more equitable access to care and evidence that informs policy and practice.